-+ 0.00%
-+ 0.00%
-+ 0.00%

COGENT BIOSCIENCES ANNOUNCES DETAILED CLINICAL DATA FROM PEAK PHASE 3 TRIAL WITH BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN GASTROINTESTINAL STROMAL TUMORS (GIST) AT 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

Reuters·05/30/2026 12:00:01

Please log in to view news